- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03615144
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10065
- Memorial SloanKettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Subject Inclusion Criteria:
- Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is indicated including:
Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least one of the following criteria (Walters et al):
- Cerebrovascular accident lasting longer than 24 hours
- Impaired neuropsychological function with abnormal brain MRI/MRA
- Recurrent hospitalizations (>2 episodes/year over several years) or exchange transfusions for acute chest syndrome
- Recurrent priapism
- Stage I or II sickle chronic lung disease
- Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration rate 30-50% of predicted normal value for age)
- Bilateral proliferative retinopathy with major visual impairment in at least one eye
- Osteonecrosis of multiple joints
- Red cell alloimmunization during chronic transfusion therapy
Thalassemia major with at least one of the following criteria:
- Age <16 years
- Available HLA-identical sibling
- Red blood cell transfusion dependency
- Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy)
- Recurrence of disease after previous stem cell transplant
Bone Marrow Failure Syndromes:
- Aplastic anemia refractory to immunosuppressive therapy
- Diamond Blackfan Anemia refractory to conventional therapy
- Shwachman-Diamond Syndrome
- Severe Congenital Neutropenia
- Congenital Amegakaryocytic Thrombocytopenia
- Thrombocytopenia Absent Radii syndrome
- Other marrow failure disorders not otherwise specified
Autoimmune cytopenias refractory to all conventional treatments
- Autoimmune hemolytic anemia
- Immune thrombocytopenia
- Evan's syndrome
- Pure red cell aplasia
Histiocytic disorders:
- Hemophagocytic lymphohistiocytosis
- High risk, recurrent or refractory Langerhans cell histiocytosis
- Secondary HLH
Subject Inclusion Criteria:
- Recipient's age birth to < 70 years old
- Patients must have adequate organ function measured by:
- Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must improve with exercise.
- Hepatic: < 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant for. Patients with higher bilirubin levels due to causes other than active liver disease are also eligible with PI approval e.g. patients with PNH, Gilbert"s disease or other hemolytic disorders.
- Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for hemoglobin).
- Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 70 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.
- Normal GFR in Children and Young Adults.
Donor Inclusion Criteria:
- Each donor must meet criteria outlined by institutional guidelines and be medically eligible to donate according to NMDP (or equivalent donor search organization) criteria including testing for antibodies to Human TLymphotrophic Virus Types I & II (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and Zika.
- Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter.
- Donor should be healthy and agree to receive G-CSF followed by donation of peripheral blood stem cells.
- Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC collection).
- Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A, B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched.
Subject Exclusion Criteria:
- Female patients who are pregnant or breast-feeding
- Active viral, bacterial or fungal infection
- Patient seropositive for HIV-I/II; HTLV-I/II
- Karnofsky (adult)/Lansky (pediatric) < 70%
- Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are presently undergoing transplantation based on a multi-center protocol
- Patients with Thalassemia major with Pesaro risk score >II
- Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII), α-Mannosidosis, X- ALD, Osteopetrosis
Donor Exclusion Criteria:
- Donors who are seropositive for HIV-I/II or HTLV-I/II and female patients who are pregnant or breastfeeding will not be eligible for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
ACTIVE_COMPARATOR: Melphalan/Thiotepa/Clofarabine
Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
|
Melphalan 70 mg/m2/day x 2
Thiotepa 7.5 mg/kg/day x 2
Clofarabine 20-30 mg/m2/day x 5
antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
|
ACTIVE_COMPARATOR: Melphalan/Thiotepa/ Fludarabine
Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning.
|
Melphalan 70 mg/m2/day x 2
Thiotepa 7.5 mg/kg/day x 2
antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
Fludarabine 30 mg/m2/day x 5
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival (OS)
Time Frame: 2 years
|
Overall survival is defined as time from transplant to death or last follow-up.
Rate greater than 0.75 would be considered a success.
|
2 years
|
Collaborators and Investigators
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hematologic Diseases
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Clofarabine
- Melphalan
- Fludarabine
- Thiotepa
- Thymoglobulin
- Antilymphocyte Serum
Other Study ID Numbers
- 17-596
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Malignant Hematologic Disorders
-
Institut Paoli-CalmettesCompletedHodgkin Lymphoma | Acute Leukemia | Non-hodgkin Lymphoma | Malignant HaemopathiesFrance
-
Rajni AgarwalCompletedMalignant Diseases | Non-malignant DiseasesUnited States
-
Johann Wolfgang Goethe University HospitalTerminatedMalignant and Non-malignant High Risk DiseasesGermany
-
Yonsei UniversityUnknownMalignant Hematologic DisorderKorea, Republic of
-
Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)RecruitingNon-Malignant NeoplasmUnited States
-
Washington University School of MedicineSt. Louis Children's HospitalRecruitingHemoglobinopathies | Metabolic Disorders | Hematologic, Immune, or Bone Marrow Disorders | Non-malignant DisordersUnited States, Canada
-
Asan Medical CenterUnknownHaploidentical Hematopoietic Stem Cell Transplantation | Malignant Disease | Non-malignant DiseaseKorea, Republic of
-
Sun Yat-sen UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Sixth Affiliated Hospital...Unknown
-
National Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin LymphomaUnited States
-
Mundipharma Research GmbH & Co KGCompletedNon-malignant Pain | Malignant PainGermany
Clinical Trials on Melphalan
-
Hadassah Medical OrganizationUnknown
-
Uppsala UniversityDalarna County Council, Sweden; Uppsala County Council, SwedenNot yet recruitingMyeloma Multiple
-
University of California, San FranciscoTerminatedMultiple Myeloma | Patient ParticipationUnited States
-
Delcath Systems Inc.WithdrawnHepatocellular Carcinoma (HCC)United States
-
Duke UniversityCompletedLymphoma | Leukemia | Ovarian Cancer | Brain and Central Nervous System Tumors | Extragonadal Germ Cell TumorUnited States
-
Hadassah Medical OrganizationTerminated
-
Delcath Systems Inc.Active, not recruitingBile Duct Cancer | Intrahepatic CholangiocarcinomaUnited States
-
University of ArizonaCompletedHematologic Neoplasms | Multiple Myeloma | Myelofibrosis | Anemia, Aplastic | Hemoglobinuria, ParoxysmalUnited States
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedRetinoblastomaUnited States
-
Adherex Technologies, Inc.CompletedNeoplasmsUnited States